{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T21:20:52Z","timestamp":1795296052047,"version":"4.10.3"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41582-026-01185-z","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:03:42Z","timestamp":1771002222000},"page":"139-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Towards biomarker-based diagnosis of Parkinson disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-0854","authenticated-orcid":false,"given":"Eduardo","family":"Tolosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-0971","authenticated-orcid":false,"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Noyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-3802","authenticated-orcid":false,"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mahlknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/brain\/awx035","volume":"140","author":"A Lees","year":"2017","unstructured":"Lees, A. An essay on the shaking palsy. Brain 140, 843\u2013848 (2017).","journal-title":"Brain"},{"key":"1185_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","volume":"33","author":"RB Postuma","year":"2018","unstructured":"Postuma, R. B. et al. Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 33, 1601\u20131608 (2018).","journal-title":"Mov. Disord."},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mds.29317","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul, S., Revesz, T., Jaunmuktane, Z., Warner, T. T. & De Pablo-Fernandez, E. Clinical diagnostic accuracy of Parkinson\u2019s disease: where do we stand? Mov. Disord. 38, 558\u2013566 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/mds.29556","volume":"38","author":"TG Beach","year":"2023","unstructured":"Beach, T. G. et al. Accuracy of the early diagnosis of Parkinson\u2019s disease. Mov. Disord. 38, 1573\u20131574 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg, D. et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 30, 1600\u20131611 (2015).","journal-title":"Mov. Disord."},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel, S. et al. Update of the MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 34, 1464\u20131470 (2019).","journal-title":"Mov. Disord."},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(13)70056-5","volume":"12","author":"A Iranzo","year":"2013","unstructured":"Iranzo, A. et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12, 443\u2013453 (2013).","journal-title":"Lancet Neurol."},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma, R. B. et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744\u2013759 (2019).","journal-title":"Brain"},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1474-4422(24)00402-2","volume":"23","author":"G May\u00e0","year":"2024","unstructured":"May\u00e0, G. et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. Lancet Neurol. 23, 1238\u20131251 (2024).","journal-title":"Lancet Neurol."},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.23589","volume":"72","author":"LI McGuire","year":"2012","unstructured":"McGuire, L. I. et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt\u2013Jakob disease. Ann. Neurol. 72, 278\u2013285 (2012).","journal-title":"Ann. Neurol."},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer, A. et al. \u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid \u2014 a systematic review and meta-analysis. Mov. Disord. Clin. Pract. 10, 737\u2013747 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo, A. et al. Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 20, 203\u2013212 (2021).","journal-title":"Lancet Neurol."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz, M. et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578, 273\u2013277 (2020).","journal-title":"Nature"},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-025-00469-6","volume":"14","author":"JA Wiseman","year":"2025","unstructured":"Wiseman, J. A., Turner, C. P., Faull, R. L. M., Halliday, G. M. & Dieriks, B. V. Refining \u03b1-synuclein seed amplification assays to distinguish Parkinson\u2019s disease from multiple system atrophy. Transl. Neurodegener. 14, 7 (2025).","journal-title":"Transl. Neurodegener."},{"key":"1185_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","volume":"23","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 23, 1225\u20131237 (2024).","journal-title":"Lancet Neurol."},{"key":"1185_CR22","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"Alex Iranzo","year":"2023","unstructured":"Iranzo, A. lex et al. Misfolded \u03b1-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology 100, e1944\u2013e1954 (2023).","journal-title":"Neurology"},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1111\/ene.16041","volume":"30","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Comparison of biospecimens for \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease: a systematic review and network meta-analysis. Eur. J. Neurol. 30, 3949\u20133967 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA 331, 1298\u20131306 (2024).","journal-title":"JAMA"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi, A. et al. Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448\u20131455 (2023).","journal-title":"Nat. Med."},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge, A. et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain 145, 3058\u20133071 (2022).","journal-title":"Brain"},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.tibtech.2024.01.007","volume":"42","author":"C Soto","year":"2024","unstructured":"Soto, C. \u03b1-Synuclein seed amplification technology for Parkinson\u2019s disease and related synucleinopathies. Trends Biotechnol. 42, 829\u2013841 (2024).","journal-title":"Trends Biotechnol."},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1002\/alz.13818","volume":"20","author":"J Levin","year":"2024","unstructured":"Levin, J. et al. \u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer\u2019s disease late in the disease course and dependent on Lewy pathology burden. Alzheimers Dement. 20, 4351\u20134365 (2024).","journal-title":"Alzheimers Dement."},{"key":"1185_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga, G. M. et al. Performance of a seed amplification assay for misfolded \u03b1-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 147, 18 (2024).","journal-title":"Acta Neuropathol."},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-024-01923-8","volume":"13","author":"S Br\u00e4uer","year":"2025","unstructured":"Br\u00e4uer, S., Schniewind, I., Dinter, E. & Falkenburger, B. H. Recursive seed amplification detects distinct \u03b1-synuclein strains in cerebrospinal fluid of patients with Parkinson\u2019s disease. Acta Neuropathol. Commun. 13, 13 (2025).","journal-title":"Acta Neuropathol. Commun."},{"key":"1185_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"D Orr\u00fa","year":"2025","unstructured":"Orr\u00fa, D. et al. Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study. Lancet Neurol. 24, 580\u2013590 (2025).","journal-title":"Lancet Neurol."},{"key":"1185_CR32","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/mds.30019","volume":"39","author":"DP Vaughan","year":"2024","unstructured":"Vaughan, D. P. et al. Evaluation of cerebrospinal fluid \u03b1-synuclein seed amplification assay in progressive supranuclear palsy and corticobasal syndrome. Mov. Disord. 39, 2285\u20132291 (2024).","journal-title":"Mov. Disord."},{"key":"1185_CR33","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"1185_CR34","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo, G. et al. Investigating \u03b1-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid \u03b1-synuclein seed amplification assay. Alzheimers Dement. 20, 2444\u20132452 (2024).","journal-title":"Alzheimers Dement."},{"key":"1185_CR35","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1002\/alz.14276","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun, D. et al. Association of CSF \u03b1-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer\u2019s disease neuroimaging initiative study. Alzheimers Dement. 20, 8444\u20138460 (2024).","journal-title":"Alzheimers Dement."},{"key":"1185_CR36","doi-asserted-by":"publisher","unstructured":"Beach, T. G. et al. Parkinson disease neuropathological comorbidities: prevalences from younger-old to older-old, with comparison to non-demented, non-Parkinsonian subjects. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.01.13.25319971 (2025).","DOI":"10.1101\/2025.01.13.25319971"},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer, W. et al. \u03b1-Synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann. Neurol. 88, 503\u2013512 (2020).","journal-title":"Ann. Neurol."},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ana.26089","volume":"89","author":"W Singer","year":"2021","unstructured":"Singer, W. et al. \u03b1-Synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann. Neurol. 89, 1212\u20131220 (2021).","journal-title":"Ann. Neurol."},{"key":"1185_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"1185_CR40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4172\/2161-0460.1000444","volume":"8","author":"DJ Irwin","year":"2018","unstructured":"Irwin, D. J. & Hurtig, H. I. The contribution of tau, amyloid-\u03b2 and \u03b1-synuclein pathology to dementia in Lewy body disorders. J. Alzheimers Dis. Parkinsonism 8, 444 (2018).","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"key":"1185_CR41","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","volume":"266","author":"EW Lim","year":"2019","unstructured":"Lim, E. W. et al. Amyloid-\u03b2 and Parkinson\u2019s disease. J. Neurol. 266, 2605\u20132619 (2019).","journal-title":"J. Neurol."},{"key":"1185_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JPD-230154","volume":"14","author":"L Walker","year":"2024","unstructured":"Walker, L. & Attems, J. Prevalence of concomitant pathologies in Parkinson\u2019s disease: implications for prognosis, diagnosis, and insights into common pathogenic mechanisms. J. Parkinsons Dis. 14, 35\u201352 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","volume":"12","author":"W Paslawski","year":"2023","unstructured":"Paslawski, W. et al. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl. Neurodegen. 12, 42 (2023).","journal-title":"Transl. Neurodegen."},{"key":"1185_CR44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira, J. B. et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat. Aging 3, 1201\u20131209 (2023).","journal-title":"Nat. Aging"},{"key":"1185_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M Del Campo","year":"2023","unstructured":"Del Campo, M. et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat. Commun. 14, 5635 (2023).","journal-title":"Nat. Commun."},{"key":"1185_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge, J. et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. 147, 52 (2024).","journal-title":"Acta Neuropathol."},{"key":"1185_CR47","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/mds.29835","volume":"39","author":"S Khosousi","year":"2024","unstructured":"Khosousi, S. et al. Increased CSF DOPA decarboxylase correlates with lower DaT-SPECT binding: analyses in Biopark and PPMI cohorts. Mov. Disord. 39, 1881\u20131885 (2024).","journal-title":"Mov. Disord."},{"key":"1185_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","volume":"13","author":"E Appleton","year":"2024","unstructured":"Appleton, E. et al. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease. Transl. Neurodegen. 13, 31 (2024).","journal-title":"Transl. Neurodegen."},{"key":"1185_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56293-z","volume":"16","author":"K Bolsewig","year":"2025","unstructured":"Bolsewig, K. et al. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nat. Commun. 16, 1139 (2025).","journal-title":"Nat. Commun."},{"key":"1185_CR50","doi-asserted-by":"publisher","unstructured":"Sturchio, A. et al. High cerebrospinal DOPA decarboxylase level predicts cognitive decline in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.70367 (2025).","DOI":"10.1002\/mdc3.70367"},{"key":"1185_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002931","volume":"16","author":"M Posavi","year":"2019","unstructured":"Posavi, M. et al. Characterization of Parkinson\u2019s disease using blood-based biomarkers: a multicohort proteomic analysis. PLoS Med. 16, e1002931 (2019).","journal-title":"PLoS Med."},{"key":"1185_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J H\u00e4llqvist","year":"2024","unstructured":"H\u00e4llqvist, J. et al. Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset. Nat. Commun. 15, 4759 (2024).","journal-title":"Nat. Commun."},{"key":"1185_CR53","doi-asserted-by":"publisher","first-page":"eabo1557","DOI":"10.1126\/scitranslmed.abo1557","volume":"15","author":"R Qi","year":"2023","unstructured":"Qi, R. et al. A blood-based marker of mitochondrial DNA damage in Parkinson\u2019s disease. Sci. Transl. Med. 15, eabo1557 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1185_CR54","doi-asserted-by":"publisher","first-page":"eadl6442","DOI":"10.1126\/sciadv.adl6442","volume":"10","author":"Z Yu","year":"2024","unstructured":"Yu, Z. et al. Molecular beacon-based detection of circulating microRNA-containing extracellular vesicle as an \u03b1-synucleinopathy biomarker. Sci. Adv. 10, eadl6442 (2024).","journal-title":"Sci. Adv."},{"key":"1185_CR55","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","volume":"78","author":"T Mitchell","year":"2021","unstructured":"Mitchell, T. et al. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. JAMA Neurol. 78, 1262\u20131272 (2021).","journal-title":"JAMA Neurol."},{"key":"1185_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mdc3.13354","volume":"9","author":"C Peralta","year":"2021","unstructured":"Peralta, C. et al. Pragmatic approach on neuroimaging techniques for the differential diagnosis of parkinsonisms. Mov. Disord. Clin. Pract. 9, 6\u201319 (2021).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1185_CR57","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/brainsci12091146","volume":"12","author":"S Prange","year":"2022","unstructured":"Prange, S., Theis, H., Banwinkler, M. & van Eimeren, T. Molecular imaging in Parkinsonian disorders \u2014 what\u2019s new and hot? Brain Sci. 12, 1146 (2022).","journal-title":"Brain Sci."},{"key":"1185_CR58","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari, L. et al. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88, 1461\u20131467 (2017).","journal-title":"Neurology"},{"key":"1185_CR59","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.3233\/JPD-230385","volume":"14","author":"H Theis","year":"2024","unstructured":"Theis, H., Pavese, N., Rektorova, I. & van Eimeren, T. Imaging biomarkers in prodromal and earliest phases of Parkinson\u2019s disease. J. Parkinsons Dis. 14, S353\u2013S365 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR60","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/mds.28139","volume":"35","author":"A Siderowf","year":"2020","unstructured":"Siderowf, A. et al. Clinical and imaging progression in the PARS cohort: long-term follow-up. Mov. Disord. 35, 1550\u20131557 (2020).","journal-title":"Mov. Disord."},{"key":"1185_CR61","doi-asserted-by":"publisher","first-page":"105567","DOI":"10.1016\/j.ebiom.2025.105567","volume":"112","author":"K Marek","year":"2025","unstructured":"Marek, K. et al. Evidence for \u03b1-synuclein aggregation in older individuals with hyposmia: a cross-sectional study. eBioMed 112, 105567 (2025).","journal-title":"eBioMed"},{"key":"1185_CR62","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25026","volume":"82","author":"A Iranzo","year":"2017","unstructured":"Iranzo, A. et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 82, 419\u2013428 (2017).","journal-title":"Ann. Neurol."},{"key":"1185_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/acn3.51269","volume":"8","author":"LM Chahine","year":"2021","unstructured":"Chahine, L. M. et al. Dopamine transporter imaging predicts clinically-defined \u03b1-synucleinopathy in REM sleep behavior disorder. Ann. Clin. Transl. Neurol. 8, 201\u2013212 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1185_CR64","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ana.26902","volume":"95","author":"D Arnaldi","year":"2024","unstructured":"Arnaldi, D. et al. Presynaptic dopaminergic imaging characterizes patients with REM sleep behavior disorder due to synucleinopathy. Ann. Neurol. 95, 1178\u20131192 (2024).","journal-title":"Ann. Neurol."},{"key":"1185_CR65","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.parkreldis.2009.12.010","volume":"16","author":"K Kashihara","year":"2010","unstructured":"Kashihara, K., Imamura, T. & Shinya, T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson\u2019s disease. Parkinsonism Relat. Disord. 16, 252\u2013255 (2010).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1185_CR66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172460","volume":"134","author":"DS Goldstein","year":"2024","unstructured":"Goldstein, D. S. et al. Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J. Clin. Invest. 134, e172460 (2024).","journal-title":"J. Clin. Invest."},{"key":"1185_CR67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang, C. C. et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 9, 149\u2013158 (2010).","journal-title":"Lancet Neurol."},{"key":"1185_CR68","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1212\/WNL.0000000000000130","volume":"82","author":"F Holtbernd","year":"2014","unstructured":"Holtbernd, F. et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 82, 620\u2013627 (2014).","journal-title":"Neurology"},{"key":"1185_CR69","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1007\/s00259-023-06289-y","volume":"50","author":"G Carli","year":"2023","unstructured":"Carli, G. et al. Occipital hypometabolism is a risk factor for conversion to Parkinson\u2019s disease in isolated REM sleep behaviour disorder. Eur. J. Nucl. Med. Mol. Imaging 50, 3290\u20133301 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1185_CR70","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00702-017-1717-8","volume":"124","author":"B Heim","year":"2017","unstructured":"Heim, B., Krismer, F., De Marzi, R. & Seppi, K. Magnetic resonance imaging for the diagnosis of Parkinson\u2019s disease. J. Neural Transm. 124, 915\u2013964 (2017).","journal-title":"J. Neural Transm."},{"key":"1185_CR71","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/01.wnr.0000227984.84927.a7","volume":"17","author":"M Sasaki","year":"2006","unstructured":"Sasaki, M. et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson\u2019s disease. Neuroreport 17, 1215\u20131218 (2006).","journal-title":"Neuroreport"},{"key":"1185_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/mdc3.12590","volume":"5","author":"N Pavese","year":"2018","unstructured":"Pavese, N. & Yen, F. T. Nigrosome imaging and neuromelanin sensitive MRI in diagnostic evaluation of parkinsonism. Mov. Disord. Clin. Pract. 5, 131\u2013140 (2018).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1185_CR73","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/brain\/aww006","volume":"139","author":"M Ehrminger","year":"2016","unstructured":"Ehrminger, M. et al. The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139, 1180\u20131188 (2016).","journal-title":"Brain"},{"key":"1185_CR74","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.28933","volume":"37","author":"R Gaurav","year":"2022","unstructured":"Gaurav, R. et al. Deep learning-based neuromelanin MRI changes of isolated REM sleep behavior disorder. Mov. Disord. 37, 1064\u20131069 (2022).","journal-title":"Mov. Disord."},{"key":"1185_CR75","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.30119","volume":"40","author":"P Trujillo","year":"2025","unstructured":"Trujillo, P. et al. Central involvement in pure autonomic failure: insights from neuromelanin-sensitive magnetic resonance imaging and 18F-fluorodopa-positron emission tomography. Mov. Disord. 40, 716\u2013726 (2025).","journal-title":"Mov. Disord."},{"key":"1185_CR76","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/ejn.16296","volume":"59","author":"Y Yan","year":"2024","unstructured":"Yan, Y., Zhang, M., Ren, W., Zheng, X. & Chan, Y. Neuromelanin-sensitive magnetic resonance imaging: possibilities and promises as an imaging biomarker for Parkinson\u2019s disease. Eur. J. Neurosci. 59, 2616\u20132627 (2024).","journal-title":"Eur. J. Neurosci."},{"key":"1185_CR77","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.10100495","volume":"257","author":"C Langkammer","year":"2010","unstructured":"Langkammer, C. et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257, 455\u2013462 (2010).","journal-title":"Radiology"},{"key":"1185_CR78","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3174\/ajnr.A4260","volume":"36","author":"Y Murakami","year":"2015","unstructured":"Murakami, Y. et al. Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. Am. J. Neuroradiol. 36, 1102\u20131108 (2015).","journal-title":"Am. J. Neuroradiol."},{"key":"1185_CR79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuroimage.2019.02.016","volume":"191","author":"X Li","year":"2019","unstructured":"Li, X. et al. Multi-atlas tool for automated segmentation of brain gray matter nuclei and quantification of their magnetic susceptibility. NeuroImage 191, 337\u2013349 (2019).","journal-title":"NeuroImage"},{"key":"1185_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162460","volume":"11","author":"C Langkammer","year":"2016","unstructured":"Langkammer, C. et al. Quantitative susceptibility mapping in Parkinson\u2019s disease. PLoS ONE 11, e0162460 (2016).","journal-title":"PLoS ONE"},{"key":"1185_CR81","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1212\/WNL.0b013e31829e6fd2","volume":"81","author":"AI Blazejewska","year":"2013","unstructured":"Blazejewska, A. I. et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 81, 534\u2013540 (2013).","journal-title":"Neurology"},{"key":"1185_CR82","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/mds.26932","volume":"32","author":"P Mahlknecht","year":"2017","unstructured":"Mahlknecht, P., Krismer, F., Poewe, W. & Seppi, K. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson\u2019s disease. Mov. Disord. 32, 619\u2013623 (2017).","journal-title":"Mov. Disord."},{"key":"1185_CR83","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1007\/s00415-021-10582-x","volume":"268","author":"SJ Cho","year":"2021","unstructured":"Cho, S. J. et al. Iron-sensitive magnetic resonance imaging in Parkinson\u2019s disease: a systematic review and meta-analysis. J. Neurol. 268, 4721\u20134736 (2021).","journal-title":"J. Neurol."},{"key":"1185_CR84","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ana.24646","volume":"79","author":"R De Marzi","year":"2016","unstructured":"De Marzi, R. et al. Loss of dorsolateral nigral hyperintensity on 3.0 Tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 79, 1026\u20131030 (2016).","journal-title":"Ann. Neurol."},{"key":"1185_CR85","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/awx146","volume":"140","author":"RG Burciu","year":"2017","unstructured":"Burciu, R. G. et al. Progression marker of Parkinson\u2019s disease: a 4-year multi-site imaging study. Brain 140, 2183\u20132192 (2017).","journal-title":"Brain"},{"key":"1185_CR86","doi-asserted-by":"publisher","first-page":"fcae344","DOI":"10.1093\/braincomms\/fcae344","volume":"6","author":"ER Tobin","year":"2024","unstructured":"Tobin, E. R. et al. Functional and free-water imaging in rapid eye movement behaviour disorder and Parkinson\u2019s disease. Brain Commun. 6, fcae344 (2024).","journal-title":"Brain Commun."},{"key":"1185_CR87","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"1185_CR88","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton, A. B. et al. alpha-Synuclein locus triplication causes Parkinson\u2019s disease. Science 302, 841 (2003).","journal-title":"Science"},{"key":"1185_CR89","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605\u2013608 (1998).","journal-title":"Nature"},{"key":"1185_CR90","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente, E. M. et al. Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science 304, 1158\u20131160 (2004).","journal-title":"Science"},{"key":"1185_CR91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1077209","volume":"299","author":"V Bonifati","year":"2003","unstructured":"Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256\u2013259 (2003).","journal-title":"Science"},{"key":"1185_CR92","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"1185_CR93","doi-asserted-by":"publisher","unstructured":"Leonard, H. L. & Global Parkinson\u2019s Genetics Program (GP2). Novel Parkinson\u2019s disease genetic risk factors within and across European populations. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.03.14.24319455 (2025).","DOI":"10.1101\/2025.03.14.24319455"},{"key":"1185_CR94","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case\u2013control study. Lancet Neurol. 7, 583\u2013590 (2008).","journal-title":"Lancet Neurol."},{"key":"1185_CR95","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1185_CR96","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajhg.2016.01.014","volume":"98","author":"S Lesage","year":"2016","unstructured":"Lesage, S. et al. Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1\/Parkin-dependent mitophagy. Am. J. Hum. Genet. 98, 500\u2013513 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"1185_CR97","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","volume":"23","author":"EK Gustavsson","year":"2024","unstructured":"Gustavsson, E. K. et al. RAB32 Ser71Arg in autosomal dominant Parkinson\u2019s disease: linkage, association, and functional analyses. Lancet Neurol. 23, 603\u2013614 (2024).","journal-title":"Lancet Neurol."},{"key":"1185_CR98","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/mds.29500","volume":"38","author":"G Pal","year":"2023","unstructured":"Pal, G. et al. Genetic testing in Parkinson\u2019s disease. Mov. Disord. 38, 1384\u20131396 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR99","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/genes12071006","volume":"12","author":"JO Day","year":"2021","unstructured":"Day, J. O. & Mullin, S. The genetics of Parkinson\u2019s disease and implications for clinical practice. Genes 12, 1006\u20131029 (2021).","journal-title":"Genes"},{"key":"1185_CR100","doi-asserted-by":"publisher","first-page":"fcaf103","DOI":"10.1093\/braincomms\/fcaf103","volume":"7","author":"LM Chahine","year":"2025","unstructured":"Chahine, L. M. et al. LRRK2-associated parkinsonism with and without in vivo evidence of \u03b1-synuclein aggregates: longitudinal clinical and biomarker characterization. Brain Commun. 7, fcaf103 (2025).","journal-title":"Brain Commun."},{"key":"1185_CR101","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/acn3.772","volume":"6","author":"Aet al Garrido","year":"2019","unstructured":"Garrido, A. et al. \u03b1-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 6, 1024\u20131032 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1185_CR102","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/alz.13858","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun, D. et al. A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function. Alzheimers Dement. 20, 5114\u20135131 (2024).","journal-title":"Alzheimers Dement."},{"key":"1185_CR103","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan, L. et al. Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain 145, 3454\u20133471 (2022).","journal-title":"Brain"},{"key":"1185_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu, Y. et al. Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain 147, 444\u2013457 (2024).","journal-title":"Brain"},{"key":"1185_CR105","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","volume":"19","author":"JB Toledo","year":"2023","unstructured":"Toledo, J. B. et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimers Dement. 19, 318\u2013332 (2023).","journal-title":"Alzheimers Dement."},{"key":"1185_CR106","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo, G. et al. \u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99, 195\u2013205 (2022).","journal-title":"Neurology"},{"key":"1185_CR107","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210279","volume":"104","author":"DG Coughlin","year":"2025","unstructured":"Coughlin, D. G. et al. \u03b1-synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology 104, e210279 (2025).","journal-title":"Neurology"},{"key":"1185_CR108","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"1185_CR109","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.0000000000200897","volume":"99","author":"EA Macklin","year":"2022","unstructured":"Macklin, E. A., Coffey, C. S., Brumm, M. C. & Seibyl, J. P. Statistical considerations in the design of clinical trials targeting prodromal Parkinson disease. Neurology 99, 68\u201375 (2022).","journal-title":"Neurology"},{"key":"1185_CR110","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.3233\/JPD-240164","volume":"14","author":"GF Crotty","year":"2024","unstructured":"Crotty, G. F., Ayer, S. J. & Schwarzshild, M. A. Designing the first trials for Parkinson\u2019s prevention. J. Parkinsons Dis. 14, S381\u2013S393 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR111","doi-asserted-by":"publisher","first-page":"981249","DOI":"10.3389\/fneur.2022.981249","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Efficacy of idebenone in the treatment of iRBD into synucleinopathies (EITRS): rationale, design, and methodology of a randomized, double-blind, multi-center clinical study. Front. Neurol. 13, 981249 (2022).","journal-title":"Front. Neurol."},{"key":"1185_CR112","unstructured":"US National Library of Medicine. Slow-SPEED-NL: slowing Parkinson\u2019s early through exercise dosage \u2014 Netherlands (Slow-SPEED-NL). ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06193252 (2025)."},{"key":"1185_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"1185_CR114","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557 (2024).","journal-title":"Neuron"},{"key":"1185_CR115","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1515\/cclm-2023-1472","volume":"62","author":"A Mammana","year":"2024","unstructured":"Mammana, A. et al. Improving protocols for \u03b1-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification. Clin. Chem. Lab. Med. 62, 2001\u20132010 (2024).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1185_CR116","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt, A. M. et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. 149, 20 (2025).","journal-title":"Acta Neuropathol."},{"key":"1185_CR117","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.98.18_supplement.1529","volume":"98","author":"E Brown","year":"2022","unstructured":"Brown, E. et al. Parkinson\u2019s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson\u2019s disease (PD) (P9-11.006). Neurology 98, 1529 (2022).","journal-title":"Neurology"},{"key":"1185_CR118","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41531-021-00176-9","volume":"7","author":"JP Bestwick","year":"2021","unstructured":"Bestwick, J. P. et al. Improving estimation of Parkinson\u2019s disease risk-the enhanced PREDICT-PD algorithm. npj Parkinsons Dis. 7, 33 (2021).","journal-title":"npj Parkinsons Dis."},{"key":"1185_CR119","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.3233\/JPD-230428","volume":"14","author":"E Schaeffer","year":"2024","unstructured":"Schaeffer, E., Yilmaz, R., St Louis, E. K. & Noyce, A. J. Ethical considerations for identifying individuals in the prodromal\/early phase of Parkinson\u2019s disease: a narrative review. J. Parkinsons Dis. 14, S307\u2013S319 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR120","doi-asserted-by":"publisher","first-page":"e2037","DOI":"10.1212\/WNL.0000000000009400","volume":"94","author":"E Schaeffer","year":"2020","unstructured":"Schaeffer, E. et al. Patients\u2019 views on the ethical challenges of early Parkinson disease detection. Neurology 94, e2037\u2013e2044 (2020).","journal-title":"Neurology"},{"key":"1185_CR121","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.29403","volume":"38","author":"L P\u00e9rez-Carbonell","year":"2023","unstructured":"P\u00e9rez-Carbonell, L. et al. The views of patients with isolated rapid eye movement sleep behavior disorder on risk disclosure. Mov. Disord. 38, 1089\u20131093 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR122","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mdc3.14264","volume":"12","author":"P Mahlknecht","year":"2025","unstructured":"Mahlknecht, P. et al. Preferences regarding disclosure of risk for Parkinson\u2019s disease in a population-based study. Mov. Disord. Clin. Pract. 12, 203\u2013209 (2025).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1185_CR123","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2025.0112","volume":"82","author":"DE Vaillancourt","year":"2025","unstructured":"Vaillancourt, D. E. et al. Automated imaging differentiation for parkinsonism. JAMA Neurol. 82, 495\u2013505 (2025).","journal-title":"JAMA Neurol."},{"key":"1185_CR124","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209531","volume":"103","author":"J You","year":"2024","unstructured":"You, J. et al. Prediction of future Parkinson disease using plasma proteins combined with clinical-demographic measures. Neurology 103, e209531 (2024).","journal-title":"Neurology"},{"key":"1185_CR125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/mds.30056","volume":"40","author":"P R\u00e1bano-Su\u00e1rez","year":"2025","unstructured":"R\u00e1bano-Su\u00e1rez, P. et al. Digital outcomes as biomarkers of disease progression in early Parkinson\u2019s disease: a systematic review. Mov. Disord. 40, 184\u2013203 (2025).","journal-title":"Mov. Disord."},{"key":"1185_CR126","doi-asserted-by":"publisher","first-page":"102013","DOI":"10.1016\/j.arr.2023.102013","volume":"90","author":"R Gupta","year":"2023","unstructured":"Gupta, R., Kumari, S., Senapati, A., Ambasta, R. K. & Kumar, P. New era of artificial intelligence and machine learning-based detection, diagnosis, and therapeutics in Parkinson\u2019s disease. Ageing Res. Rev. 90, 102013 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1185_CR127","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol, E. J. High-performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44\u201356 (2019).","journal-title":"Nat. Med."},{"key":"1185_CR128","doi-asserted-by":"publisher","first-page":"103621","DOI":"10.1016\/j.media.2025.103621","volume":"105","author":"D Schouten","year":"2025","unstructured":"Schouten, D. et al. Navigating the landscape of multimodal AI in medicine: a scoping review on technical challenges and clinical applications. Med. Image Anal. 105, 103621 (2025).","journal-title":"Med. Image Anal."},{"key":"1185_CR129","doi-asserted-by":"publisher","first-page":"1076657","DOI":"10.3389\/fnagi.2023.1076657","volume":"15","author":"RT Gerraty","year":"2023","unstructured":"Gerraty, R. T. et al. Machine learning within the Parkinson\u2019s progression markers initiative: review of the current state of affairs. Front. Aging Neurosci. 15, 1076657 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"1185_CR130","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/mds.30002","volume":"39","author":"V Dzialas","year":"2024","unstructured":"Dzialas, V. et al. Houston, we have AI problem! Quality issues with neuroimaging-based artificial intelligence in Parkinson\u2019s disease: a systematic review. Mov. Disord. 39, 2130\u20132143 (2024).","journal-title":"Mov. Disord."},{"key":"1185_CR131","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.3233\/JPD-181505","volume":"8","author":"C Klein","year":"2018","unstructured":"Klein, C., Hattori, N. & Marras, C. MDSGene: closing data gaps in genotype\u2013phenotype correlations of monogenic Parkinson\u2019s disease. J. Parkinsons Dis. 8, S25\u2013S30 (2018).","journal-title":"J. Parkinsons Dis."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01185-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01185-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01185-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:01:57Z","timestamp":1772715717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01185-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01185-z","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"15 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.T. reports honoraria for consultancy from Prevail\/Lilly and has received funding for research from the Michael J Fox Foundation. Unrelated to this work, W.P. has received personal lecture fees and\/or consultancy fees from Alterity, AbbVie, AC Immune, BIAL, Boehringer, Britannia, Lilly, Lundbeck, Merck, Merz Pharma, Mitsubishi-Tanabe, Neuroderm, Novo Nordisk, Roche, Sanofi, Sumitomo, Takeda, Teva, UCB and Zambon, and has received grant support from the Michael J Fox Foundation and the European Union programmes FP7 and Horizon, and has received royalties from Cambridge University Press, Oxford University Press, Thieme and Wiley Blackwell. A.J.N. is supported by the Michael J Fox Foundation and reports honoraria from Teva and travel and meeting expenses from the International Movement Disorders Society. P.S. has received honoraria for lectures or courses from Abbvie, Britannia, Lundbeck, Merz Therapeutics and Zambon, owns stock in Bioarctic and Irlab, and has received major research grants from Aligning Science Across Parkinson\u2019s, the Knut and Alice Wallenberg Foundation, the Michael J Fox Foundation and the Swedish Research Council. M.J.M. has received grant support from the Michael J Fox Foundation and honoraria for consultancy from Bial. P.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}